

prosci-inc.com





## HIGH PERFORMANCE ANTIBODIES ... AND MORE

**ProSci Incorporated** 12170 Flint Place Poway, CA 92064 Toll Free: +1 (888) 513 9525 Local: +1 (858) 513 2638 Fax: +1 (858) 513 2692

techsupport@prosci-inc.com

## **Dopamine Transporter Antibody**


CATALOG NUMBER: 50-205

**OFFICIAL SYMBOL:** 

GENE ID:

SLC6A3

6531



Western blot of human caudate lysate showing specific immunolabeling of the ~88k DAT protein.

Specifications	
SPECIES REACTIVITY:	Human
TESTED APPLICATIONS:	IHC, WB
APPLICATIONS:	The antibody has been tested in Western blots of SDS-solubilized human striatal samples and in IHC applications with formaldehyde-fixed human and monkey brain sections.
USER NOTE:	Optimal dilutions for each application to be determined by the researcher.
PREDICTED MOLECULAR WEIGHT:	88
IMMUNOGEN:	Peptide from the extracellular loop 2 (EL2) region of human dopamine transporter (DAT), conjugated to keyhole limpet hemocyanin (KLH).
HOST SPECIES:	Rabbit
Duomoution	
Properties	
PURIFICATION:	Affinity Purified
PHYSICAL STATE:	Liquid
BUFFER:	100 uL in 10 mM HEPES (pH 7.5), 150 mM NaCl, 100 ug per mL BSA and 50% glycerol.
STORAGE CONDITIONS:	Dopamine Transporter antibody can be stored at -20°C and is stable at -20°C for at least 1 year.
CLONALITY:	Polyclonal
CONJUGATE:	Unconjugated
Additional Info	
ALTERNATE NAMES:	DAT, DAT1, PKDYS, Solute carrier family 6 member 3, DA transporter
ACCESSION NO.:	Q01959
PROTEIN GI NO.:	266667

Background	
BACKGROUND:	The dopamine transporter (DAT) is responsible for the reaccumulation of dopamine after it has been released. DAT antibodies and antibodies for other markers of catecholamine biosynthesis are widely used as markers for dopaminergic and noradrenergic neurons in a variety of applications including depression, schizophrenia, Parkinson's disease and drug abuse (Kish et al., 2001; Zhu et al., 2000; Zhu et al., 1999). Levels of DAT protein expression are altered by chronic drug administration (Wilson et al., 1996).
REFERENCES:	1) Kish SJ, Kalasinsky KS, Derkach P, Schmunk GA, Guttman M, Ang L, Adams V, Furukawa Y, Haycock JW (2001) Striatal dopaminergic and serotonergic markers in human heroin users. Neuropsychopharmacology 24:561-567.
	2) Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ (1996) Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2:699-703.
	3) Zhu MY, Klimek V, Haycock JW, Ordway GA (2000) Quantitation of tyrosine hydroxylase protein in the locus coeruleus from postmortem human brain. J Neurosci Meth 99:37-44.

## FOR RESEARCH USE ONLY

December 13, 2016